Bi-directional sequencing of HRAS exons 2 and 3 which includes sites of common activating mutations in codons 12, 13, 59 and 61.
Samples are accepted for somatic and germline HRAS mutation testing. HRAS is highly homologous with KRAS and NRAS; all are members of the most frequently mutated family of oncogenes. HRAS mutations are found in a wide variety of solid tumors, including cancers of the bladder, thyroid, upper digestive tract, and melanoma. Germline HRAS mutations are associated with Costello syndrome, which confers a lifetime risk of approximately 15% for malignant tumors including rhabdomyosarcoma and neuroblastoma in childhood and bladder cancer in adolescence and young adulthood.
- Peripheral blood: 5 mL in EDTA tube.
- Bone marrow: 2 mL in EDTA tube.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.